![]() |
市場調査レポート
商品コード
1433469
甲状腺アブレーション装置の世界市場:2023-2030年Global Thyroid Ablation Devices Market 2023-2030 |
||||||
カスタマイズ可能
|
甲状腺アブレーション装置の世界市場:2023-2030年 |
出版日: 2024年01月21日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2~3営業日
|
世界の甲状腺アブレーション装置市場は、予測期間(2023-2030年)にCAGR 9.8%でかなりの成長が見込まれています。この市場の成長は、このデバイスの需要を生み出した甲状腺がんの有病率の増加に起因しています。2023年、米国がん協会は、米国における甲状腺がんの新規症例を約43,720例(男性12,540例、女性31,180例)と推定しています。甲状腺がんによる死亡者数は約2,120人(男性970人、女性1,150人)で、甲状腺がんと診断される平均年齢は51歳とされています。このがんは男性より女性の方が約3倍多く、白人では黒人より約70%多いです。また、2022年11月には、「高齢者人口統計」という記事が掲載された:A Portrait of Aging Americans"では、米国人口の16.3%にあたる5,410万人が65歳以上の高齢者であると報告されています。高齢者人口は2040年までに22%、2060年までに25%に増加すると予想されています。低侵襲治療手術に対する需要の高まりは、市場成長の大きな可能性をさらに生み出しています。
種類の中で、マイクロ波アブレーションサブセグメントは、予測期間中に成長すると予測されます。ジェネレーター、フレキシブルケーブル、アンテナがMWAシステムを構成します。Gland Surgeryが発表した論文"Microwave ablation for thyroid nodules:a new string to the bow for percutaneous treatments?"は、実験的研究と他の臓器での研究を記録しており、MWAは、甲状腺結節のための経皮技術の更なるステップになる可能性があり、治療時間を短縮し、ヒートシンク効果を減らし、甲状腺結節の形状に最も適合する楕円形の切除ゾーンを作る利点を与えます。
世界の甲状腺アブレーション装置市場は、北米(米国、カナダ)、欧州(英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域)、アジア太平洋地域(インド、中国、日本、韓国、その他アジア地域)、その他世界のその他の地域(中東とアフリカ、南米)を含む地域別にさらに細分化されています。中でもアジア太平洋地域は、予測期間中にかなりのCAGRで成長すると予測されています。甲状腺アブレーション装置に対する需要の増加、老人人口の増加、ヘルスケア支出の増加、甲状腺がん患者の増加などが、アジア太平洋の甲状腺アブレーション装置市場を牽引しています。
北米は、予測期間中、甲状腺アブレーション装置市場で顕著なシェアを占めると予想されています。北米市場を煽る重要な要因には、甲状腺がんの有病率の増加、低侵襲手術への嗜好の高まり、技術的に堅調なアブレーション手技の利用可能性などがあります。さらに、主要企業は、市場における甲状腺アブレーション装置の需要に応えるために、この地域へのプレゼンスを拡大しています。2023年10月、韓国の医療機器会社であるSTARmed Co.この戦略的な動きは、STARmed社の世界の拡大という広範なビジョンの一環として、北米における患者ケアの向上へのコミットメントを強調するものです。STARmed Co., Ltd.は、低侵襲な代替医療を通じて患者に快適さを提供し、熱アブレーションの革新の最前線にいます。同社は肝臓ラジオ波焼灼療法(RFA)、ラジオ波焼灼療法(RFA)に注力しており、2009年には初の甲状腺専用RF電極を開発しました。
Global Thyroid Ablation Devices Market Size, Share & Trends Analysis Report by Type (Radiofrequency Ablation, Microwave Ablation, and Others), by Product (Thermal-based Devices and Non-thermal-based Devices), By Application, (Thyroid Cancer and Thyroid Nodules), by End-use (Hospitals and Clinics, Ambulatory Surgical Centers, and Others), Forecast Period (2023-2030)
The global thyroid ablation devices market is anticipated to grow at a considerable CAGR of 9.8% during the forecast period (2023-2030). The growth of this market is attributed to the increasing prevalence of thyroid cancer which has created demand for this device. In 2023, the American Cancer Society estimated thyroid cancer in the US, about 43,720 new cases of thyroid cancer (12,540 in men and 31,180 in women). About 2,120 deaths from thyroid cancer (970 in men and 1,150 in women). The average age when a person is diagnosed with thyroid cancer is 51. This cancer is about 3 times more common in women than in men, and it is about 70% more common in white people than in black people. In addition, in November 2022, the article "Senior Population Statistics: A Portrait of Aging Americans", reported 54.1 million adults or 16.3% of the US population are seniors including aged 65 or older. The senior population is expected to rise to 22% by 2040 and 25% by 2060. The growing demand for minimally invasive treatment surgeries has further created huge scope for the market growth.
The global thyroid ablation devices market is segmented by type, product, application and end-use. Based on the type, the market is sub-segmented into radiofrequency ablation, microwave ablation, and others. Where, others include image-guided ablation. Based on the product, the market is sub-segmented into thermal-based devices, and non-thermal-based devices. Based on the application, the market is sub-segmented into thyroid cancer, and thyroid nodules. Further, based on end-use, the market is sub-segmented into hospitals and clinics, ambulatory surgical centers, and others. Where, other include cancer specialty centers. Among the end-use, the hospitals and clinics sub-segment is anticipated to hold the largest market share during the forecast period. The large share of this segment is credited to the lower costs, higher efficiency, and availability.
Among the type, microwave ablation sub-segments expected to grow over the forecast period, owing to the owing to shorter treatment duration, a broader ablation zone, and less heat sink effect. A generator, a flexible cable, and an antenna make up the MWA system. An article published by Gland Surgery, namely "Microwave ablation for thyroid nodules: a new string to the bow for percutaneous treatments?" recorded experimental studies and studies on other organs, MWA could be a further step in percutaneous techniques for thyroid nodules, giving the advantage to reduce treatment time, reduce the heat sink effect, create an ellipsoidal ablated zone which best fits with the shaping of thyroid nodules.
The global thyroid ablation devices market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East &Africa, and Latin America. Among these, Asia-Pacific is anticipated to grow at a considerable CAGR over the forecast period. The growing demand for thyroid ablation devices, increasing geriatric population, the rising healthcare expenditure, and increasing incidences of thyroid cancer cases driving the thyroid ablation devices market in the Asia-Pacific.
North America is expected to hold a prominent share in the thyroid ablation devices market during the forecast period. The significant factors fueling the North America market include increasing prevalence of thyroid cancer, growing preference for minimally invasive surgeries and availability of technically sound ablation procedures. Further, the key players are expanding their presence into the region to cater to the demand for thyroid ablation devices in the market. In October 2023,STARmed Co., Ltd., a South Korean medical device company, launched its US subsidiary, STARmed America. This strategic move underscores STARmed's commitment to improving patient care in North America as part of its broader vision for global expansion. STARmed Co., Ltd. has been at the forefront of thermal ablation innovations, offering patient comfort through minimally invasive alternatives. The company focuses on Liver Radiofrequency Ablation (RFA), Radiofrequency Ablation (RFA), and engineered the first thyroid-specific RF electrodes in 2009.
The major companies serving the thyroid ablation devices market include Boston Scientific Corp., Integra LifeSciences Corp., Johnson & Johnson Services, Inc., Medtronic Plc, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2023, the US Food and Drug Administration (FDA) cleared Baird Medical's microwave ablation (MWA) system and disposable needles for use in the US. The clearance, which is through Baird Medical subsidiary Betters Medical, means doctors in the US can now use the technology to ablate thyroid nodules, breast tumors and other diseases where soft tissue needs to be removed. In July 2023, China's National Medical Products Administration (NMPA) approved the system to treat benign thyroid nodules.